326
Views
5
CrossRef citations to date
0
Altmetric
Drug Profile

Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease

, , , , , & show all
Pages 1045-1055 | Received 06 Jun 2016, Accepted 18 Aug 2016, Published online: 01 Sep 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Fiammetta Danzo, Dejan Radovanovic, Marina Gatti, Marina Saad, Luca Perotto, Elisa Franceschi & Pierachille Santus. (2022) A reappraisal of inspiratory capacity in chronic obstructive pulmonary disease: clinical correlates and role of long-acting muscarinic antagonists and long-acting β2 agonists. Expert Review of Respiratory Medicine 16:6, pages 623-635.
Read now
Pierachille Santus, Dejan Radovanovic, Andrea Cristiano, Vincenzo Valenti & Maurizio Rizzi. (2017) Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease. Drug Design, Development and Therapy 11, pages 3257-3271.
Read now

Articles from other publishers (3)

Nalini Jayanthi, Karthickeyan Krishnan, Manali Sudhir, S. Girija, Nishi P A & Sathish Kumar J. (2022) Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease. Contemporary Clinical Trials Communications 28, pages 100931.
Crossref
Shweta Agarwal, Abhishek Sharma, Chetna Hemrajani & Poonam Negi. 2022. Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases. Advanced Drug Delivery Strategies for Targeting Chronic Inflammatory Lung Diseases 303 332 .
Swati Gulati & J. Michael Wells. (2017) Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators. Drugs 77:6, pages 651-670.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.